Recommendation for Preventive Breast Cancer Drug: Anastrozole Insights
Studies endorsed by the UK's NHS reveal that Anastrozol, over an eleven-year span, can reduce the incidence of breast cancer by approximately half. This potentially translates to preventing around 2000 cases if a quarter of eligible women opt for the treatment, with half of them adhering to the suggested five-year regimen.